Tyrosine phosphatase IA-2 (IA-2) autoantibodies have been found to be present in both LADA and T2DM patients [117,118], and it has been associated with an increased incidence of insulin therapy for T2DM patients [118]. This evidence concerns the gene INS and type 2 diabetes mellitus.